Pharsight

Ultragenyx Pharm Inc patents expiration

1. Dojolvi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186344 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Jul, 2025

(1 year, 2 months from now)

US8697748 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Apr, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-311) Jun 30, 2027
New Chemical Entity Exclusivity(NCE) Jun 30, 2025

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: 30 June, 2024

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID;ORAL

More Information on Dosage

DOJOLVI family patents

Family Patents